Lundbeck, a pharmaceutical company, has entered into a collaboration with IBM Watson Health to develop medications to treat psychiatric and neurological disorders.
Lundbeck, which will first launch projects related to schizophrenia and Parkinson's disease, will use clinical data from the Watson Health Cloud to identify new drug therapies. Lundbeck focuses on developing therapeutics related to the underlying biological mechanisms of psychiatric and neurological disorders, rather than their symptoms.
"By combining our expertise in brain research with IBM's cognitive computer technology, we expect to improve our foundation for this work, so we can develop new and improved treatments for the 425 million people who suffer from the psychiatric and neurological disorders which Lundbeck focuses on," said Anders Gersel Pedersen, executive vice president of research and development at Lundbeck.